Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?-Science-Chemical Encyclopedia-lookchem

Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
Add time:08/14/2019 Source:sciencedirect.com

ObjectiveTo evaluate the impact of periodic shortage of actinomycin-d (Act-d) in the treatment of Brazilian patients with low-risk gestational trophoblastic neoplasia (GTN) after methotrexate and folinic acid rescue (MTX/FA) resistance, treated alternately with carboplatin or etoposide as a second-line regimen.

We also recommend Trading Suppliers and Manufacturers of actinomycin K (cas 11011-00-0). Pls Click Website Link as below: cas 11011-00-0 suppliers

Prev:On the mode of action of Edeine (cas 11006-90-9): II. Studies on the binding of Edeine (cas 11006-90-9) to Escherichia coli ribosomes
Next: Modeling improved production of the chemotherapeutic polypeptide actinomycin D by a novel Streptomyces sp. strain from a Saharan soil)

Encyclopedia